Owen A. O'Connor, MD, Ph.D.
Columbia University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Owen A. O'Connor, MD, Ph.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:57 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT01998035 · Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid MalignanciesColumbia University · terminated · Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma · principal investigator
- Ph1/Ph2NCT01657331 · Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)Columbia University · completed · Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
- Ph1NCT00691210 · Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid MalignanciesColumbia University · completed · Hodgkin's Disease, Non-Hodgkin's Lymphoma
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.